Shaping the future of medicine through cell and gene therapy innovation
OXB stands at the forefront of cell and gene therapy innovation, supporting its clients deliver life-changing therapies to patients around the world. With 30 years of experience, OXB is a recognised global leader in the development and manufacture of viral vectors: a key component in cell and gene therapies that target a wide range of diseases, from rare genetic disorders to cancer.
Their proprietary platforms, cutting-edge innovation and deep scientific expertise support some of the industry’s most advanced and promising therapeutic programmes, helping accelerate the path from discovery to clinical and commercial success.
In a field where precision, safety and scalability are paramount, OXB continues to set the standard, making them the partner of choice for companies looking to bring transformative therapies to market.
Discover how OXB is shaping the future of medicine.
Visit to learn more.
A shared language for medical innovation
The Global Medical Device Nomenclature (GMDN) is the leading global standard for naming, classifying and categorising medical devices. It’s vital for healthcare professionals, regulators and manufacturers, as it provides a common language to communicate and share information, enhancing patient care and fostering innovation.
The GMDN system is used by regulators in nearly 70 countries, including the UK, USA, Canada, Australia, Brazil and more, with members in around 140 countries worldwide. It supports global harmonisation of regulatory requirements and is continually updated to reflect changes in the medical device landscape.
The GMDN Agency, a UK charity and non-profit organisation, maintains the GMDN Database. They employ expert term developers to create accurate descriptions for new products and technologies.
The full GMDN is available for free to regulators, healthcare providers and academic researchers, making it a critical component of the global regulatory infrastructure for medical devices.
Visit for more information.
Immersive patient experience for those in healthcare
Have you ever wondered what a day in the life of patients is like? Imagine facing the emotional, physical and practical challenges of living with a serious condition — not as an observer, but as the patient.
A Life in a Day offers a unique immersive simulation allowing professionals working across the life sciences to experience 24 hours in the life of a patient, helping build empathy and a deeper understanding of patient needs. This insight aims to improve outcomes for participants, the organisations they work in and ultimately, for patients.
With over 18,000 participants globally and covering more than 40 therapy areas, 92 per cent of participants go on to make patient-focused behaviour changes, leading to stronger clinical trial design, more effective conversations and better brand outcomes.
Their Interactive Showcase offers a 30-minute session where participants take part in challenges similar to those found in the A Life in a Day experience. Free to join, it provides a first-hand look at how immersive patient insight drives real change within healthcare.
To find out more, visit or register for the showcase at . You can also follow updates on LinkedIn at .
Early womb cancer detection made simple
Developed by academics at University College London (UCL), the WID-easy test is a breakthrough innovation for the early detection of womb cancer. The accurate, rapid and simple genetic test saves many from undergoing invasive surgery to determine the diagnosis.
It works by measuring chemical changes in DNA from your cervix and womb, indicating the presence or absence of cancer cells. The sample collection involves a quick, painless vaginal swab, which is analysed using a PCR test.
Every year in the UK, around 300,000 peri- and post-menopausal women experience abnormal uterine bleeding. They’re given an ultrasound scan to check for signs of cancer, which, if found, will trigger further testing, often involving highly invasive procedures, such as hysteroscopy and curettage.
Nine in ten patients referred for these procedures don’t have womb cancer, and WID-easy has been shown to detect the same number of patients with cancer as an ultrasound while reducing false positive results by nearly 90 per cent.
The WID-easy test is available for all peri- and post-menopausal patients over 45 years of age suffering from abnormal uterine bleeding. As the only test of its kind currently available in several locations across the UK, the WID-easy test is a game-changer.
ÌýLearn more and find your nearest clinic at
Engineering freedom: the rollator that climbs
Most rollators falter at the first kerb, but the Swedish-designed Veloped is a revolution in mobility. It’s engineered with a unique three-wheeled design that smoothly mounts obstacles up to 13 centimetres high. Whether it’s navigating forest trails, uneven pavements or snow-covered paths, this wheel system keeps the rollator stable, agile and surprisingly capable.
The patented climbing wheel works by distributing pressure across multiple contact points as it rolls, reducing jarring impacts and preventing sudden stops, allowing users to maintain their pace and posture.
Explore Veloped’s innovative technology soon at the Swedish innovation exhibit at Stockholm’s Technical Museum.
For a free catalogue, visit or call 0330 818 2597.
Redefining ADHD support and access
ADHD is surrounded by many narratives: long waiting lists, delayed treatment, misunderstandings and questions around medication.
ADHD 360 offer premier ADHD assessment and care, built to support you and your family. Working alongside the government and NHS, their goal is to remove stigma and shift perceptions of ADHD.
Their personalised approach ensures patients remain with the same highly trained specialist clinician throughout their journey. For private patients, their new Platinum Plus service includes a pre-assessment call with an expert to ease anxiety and explain the entire process. The assessment is undertaken by senior staff from their clinical leadership team and booked within seven days from the referral.
Patients benefit from access to an award-nominated portal, dedicated front office care and a free educational programme that supports various treatment options.
For those opting for NHS care via Right to Choose, ADHD 360 is the UK’s largest provider of NHS ADHD services. Their dedicated team collaborates with your GP to ensure you receive the best support possible.
Take control of your life and reshape your future.
To access exceptional ADHD care or learn more, visit
Electric medicine: the future of mental health
Founded in 2016, Flow Neuroscience is a Swedish health tech company aiming to make a difference in depression treatment. Their antidepressant technology provides non-invasive and safe brain stimulation, which has been scientifically proven to treat and prevent depression.
Proper medical treatment for depression should always be sought; however, with your GP’s approval, Flow can support the treatment process. It is a clinically approved at-home drug-free depression treatment consisting of a groundbreaking headset and behavioural therapy programme. The Flow headset uses a gentle electrical current to help improve your mental wellbeing by stimulating the brain using a technology called transcranial Direct Current Stimulation (tDCS). With minimal side effects, you can feel better in three weeks.
Flow has been shown to enhance mood, improve sleep and reduce anxiety. Over 40,000 people are already using Flow and 77 per cent report improvement in 21 days. It is being run in six NHS programmes successfully, with an excellent rating on Trustpilot.
Flow is the right choice for you if you’re after something that is: clinically and scientifically validated; can improve mood, motivation, sleep and anxiety; personalised; easily accessible at-home and on-demand.
Flow focuses on empowering users with clinically proven results.
Learn more at
Ìý
Healthcare wrapped in sustainability
Introducing the new Livfria® Sheath by Clinisupplies: where reliable protection meets eco-conscious design.
Each urinary sheath is individually encased in a compostable sugarcane pulp casing and is a breakthrough in sustainable continence care. Livfria’s outer packaging is also 100 per cent plastic-free and ultra-compact, minimising environmental impact without compromising functionality.
It isn’t just the packaging that sets it apart. The discreet, non-medical design offers a private, user-centred experience, subtle enough to blend into everyday life.
Designed for those who expect more—greater discretion, greater responsibility—Livfria leads the way in next-generation sheath solutions. As part of the expanding Livfria continence care range, this latest addition delivers confidence, comfort and peace of mind, without the plastic packaging.
Innovation and sustainability, designed to help people live more freely.
Visit for more.
The smarter way to sleep well
Are you doing everything you can to get a good night’s sleep? With Love CBD — a pioneer in the UK CBD industry — you’ll find yourself slipping into REM sleep before you know it.
Love CBD Sleep Patches contain melatonin, 5-HTP, lavender and linalool, promoting a healthy night’s sleep. They’re easy and convenient to use, with a slow-release method of delivery that lasts 12 hours.
The key component, melatonin, is a hormone produced by the brain that signals when it’s time to sleep, helping restore the body’s natural sleep patterns so you wake up feeling rejuvenated and refreshed. Each patch contains 3.6mg of melatonin.
Not only are you getting a peaceful night, but you’re also getting a dose of the happy hormone with 5HTP, which has been shown to raise serotonin levels within the body. Each patch contains 3.6mg of 5-HTP.
Love CBD also sells CBD patches, CBD balm, CBD tea and an extensive range of CBD oils and capsules.
Get the Love CBD Sleep Patches here and visit to use code scientist25 for a 25% discount on all Love CBD products.
Simplify diabetes management
Diabetes affects individuals from every background and lifestyle. Managing the condition, whether for yourself or a loved one, requires ongoing education, personalised care, and a clear understanding of how lifestyle, medication, and monitoring work together.
Insulet is a medical device company creating simple, innovative and human-centred products, like Omnipod® 5, dedicated to simplifying life for people
with diabetes.
Omnipod 5 is the only tubeless and waterproof* automated insulin delivery (AID) system for people with type 1 diabetes who require insulin. A discreet Pod is attached directly to the skin, which helps users manage their condition. The Omnipod 5 Pod is enhanced with a control algorithm called SmartAdjustâ„¢ technology.
Every 5 minutes, the algorithm receives glucose value and trend data from a compatible sensor, and it takes this information and predicts where glucose will be an hour into the future. It then increases, decreases, or pauses automated insulin delivery using the user’s customised target.
With Omnipod 5, Insulet aims to make diabetes management a smaller part of life and help empower more patients in managing their condition.
Visit for more.
*The Pod has a waterproof IP28 rating for up to 7 .6 metres for up to 60 minutes. The controller is not waterproof. The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older requiring insulin. The Omnipod 5 System is intended to operate as an automated insulin delivery system when used with compatible Continuous Glucose Monitors (CGM). When in automated mode, the Omnipod 5 system is designed to assist people with type 1 diabetes in achieving glycaemic targets set by their healthcare providers. It is intended to modulate (increase, decrease or pause) insulin delivery to operate within predefined threshold values using current and predicted CGM values to maintain blood glucose at
variable target glucose levels, thereby reducing glucose variability. This reduction in variability is intended to lead to a reduction in the frequency, severity, and duration of both hyperglycaemia and hypoglycaemia. The Omnipod 5 System can also operate in a manual mode that delivers insulin at set or manually adjusted rates. The Omnipod 5 System is intended for single patient use. The Omnipod 5 System is indicated for use with U-100 rapid acting insulin. Refer to the Omnipod® 5 User Guide for complete safety information including indications, contraindications, warnings, cautions, and instructions. Warning: SmartAdjust™ technology should NOT be used by anyone under the age of 2 years old. SmartAdjust™ technology should also NOT be used in people who require less than 5 units of insulin per day as the safety of the technology has not been evaluated in this population.
©2025 Insulet Corporation. Omnipod, the Omnipod 5 logo and SmartAdjust are trademarks or registered trademarks of Insulet Corporation. All rights reserved. All other trademarks are the property of their respective owners. The use of third party trademarks does not constitute an endorsement or imply a relationship or other affiliation. Insulet International, 1 King Street, 5th Floor, Hammersmith, London, INS-OHS-07-2025-00269. V1.0
Best of Health Innovation & Technology is an independent spread of advertorial from Hurst Media Company. While every care is taken in ensuring that the content is in compliance with the Advertising Standards Authority and The UK Code of Non-Broadcast Advertising and Direct & Promotional Marketing (CAP Codes), the publishers assume no responsibility in the effect rising therefrom, and readers are advised to seek professional advice before acting on any.Ìý To advertise with Best of Health Innovation & Technology, please call Hurst Media Company on 0203 478 6017. Please visit hurstmediacompany.co.uk/competition-terms-conditions for full terms and conditions
